From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)
 | Baseline (N=16) | 6 months (N=13) | 12 months (N=10) | 18 months (N=6) |
---|---|---|---|---|
Median duration of prior CAN therapy at baseline, years (min; max) | 1.0 (0; 4) | 1.0 (0; 4) | 1.0 (0; 4) | 1.5 (0; 2) |
Number (%*) of patients in disease remission (physician assessment) | 9 (60.0) | 9 (81.8) | 7 (77.8) | 4 (80.0) |
Physician Global Assessment, percentage of absent/mild-moderate/severe rating | 40 / 53 / 0 | 82 / 9 / 0 | 44 / 44 / 11 | 80 / 20 / 0 |
Patients´ assessment of current disease activity; 0–10, median (min; max) | 1.5 (0; 5) | 1.0 (0; 4) | 1.0 (0; 6) | 0.0 (0; 3) |
Patients´ assessment of current fatigue; 0–10, median (min; max) | 2.0 (0; 8) | 1.0 (0; 7) | 2,5 (0; 8) | 4.0 (0; 7) |
Number (%*) of patients without impairment of social life by the disease | 4 (50) | 5 (63) | 2 (33) | 3 (60) |
Number (%*) of patients with days absent from work/school during last 6 months | 8 (50) | 5 (39) | 5 (56) | 3 (50) |
CRP, median (mg/dl) | 0.1 | 0.1 | 0.1 | 0.0 |
SAA, median (mg/dl) | 0.5 | 0.4 | 0.4 | 0.3 |